| OHA | Oral Hypoglycemic Agents |
|---|---|
| OPV | Oral Polio-Vaccine; °æ±¸¿ë ¼Ò¾Æ¸¶ºñ ¹é½Å |
| TOPV | Trivalent Oral Polio(myelitis) Vaccine; °æ±¸¿ë ¼Ò¾Æ¸¶ºñ È¥ÇÕ¹é½Å |
| WHO ORS | World Health Organization Oral Rehydration Solution osmolality 330; ¼¼°èº¸°Ç±â±¸ °æ±¸ ¼ö¾× ¿ë¾× |
| AAOM | American Academy of Oral Medicine |
| oral teeth | <dentistry> Your centrals, laterals, and cuspids. These are the teeth in the front of your mouth. (08 Jan 1998) |
|---|---|
| oral ulcer | A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (stomatitis, aphthous), noma, necrotizing gingivitis (gingivitis, necrotizing, ulcerative), toothbrushing, and various irritants. (12 Dec 1998) |
| oral vestibule | That part of the mouth bounded anteriorly and laterally by the lips and the cheeks, posteriorly and medially by the teeth and/or gums, and above and below by the reflections of the mucosa from the lips and cheeks to the gums. Synonym: vestibulum oris, buccal cavity, vestibule of mouth. (05 Mar 2000) |
| tuberculosis, oral | Tuberculosis of the mouth, tongue, and salivary glands. (12 Dec 1998) |
| florid oral papillomatosis | Diffuse involvement of the lips and oral mucosa with benign squamous papillomas; microscopically, it resembles verrucous carcinoma, but is not invasive or localised to a specific area of the oral mucosa. (05 Mar 2000) |
| leukoedema, oral | A disorder of the buccal mucosa resembling early leukoplakia, characterised by the presence of filmy opalescence of the mucosa in the early stages to a whitish gray cast with a coarsely wrinkled surface in the later stages, associated with intracellular oedema of the spinous or malpighian layer. (12 Dec 1998) |
| leukoplakia, oral | A white patch seen on the oral mucosa. It is considered a premalignant condition and is often tobacco-induced. When evidence of epstein-barr virus is present, the condition is called hairy leukoplakia (leukoplakia, hairy). (12 Dec 1998) |
| lichen planus, oral | Oral lesions accompanying cutaneous lichen planus or often occurring alone. The buccal mucosa, lips, gingivae, floor of the mouth, and palate are usually affected (in a descending order of frequency). Typically, oral lesions consist of radiating white or gray, velvety, threadlike lines, arranged in a reticular pattern, at the intersection of which there may be minute, white, elevated dots or streaks (wickham's striae). (12 Dec 1998) |
| live oral poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acyl-(acyl-carrier-protein)-phospholipid acyltransferase | <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine Registry number: EC 2.3.1.40 Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase (26 Jun 1999) |
| acyl-(acyl-carrier-protein)-UDP-N-acetylglucosamine acyltransferase | <enzyme> E coli enzyme involved in lipid a biosynthesis; uses beta-hydroxymyristoyl-acyl carrier protein to form udp-3-monoacyl-n-acetylglucosamine; amino acid sequence given in second source Registry number: EC 2.3.1.129 Synonym: udp-aguatransferase, lpxa protein, udp-n-acetylglucosamine-3-acyltransferase, udp-n-acetylglucosamine 3-o-acyltransferase, udp-3-o-(r-3-hydroxymyristoyl)glucosamine-n-acyltransferase, lpxd protein, fira gene product, fira protein (26 Jun 1999) |
| acyl carrier protein | <protein> A small (77 peptides long) protein which binds six other enzymes involved in fatty acid synthesis. It was first isolated in E. Coli bacteria. (09 Oct 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|